4.6 Review

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 16, Issue 3, Pages 319-327

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2005.02.005

Keywords

SOST/sclerostin; sclerosteosis/Van Buchem disease; osteocyte; bone formation; BMP antagonist

Ask authors/readers for more resources

Sclerosteosis and Van Buchem disease are two closely related bone disorders characterized by progressive bone thickening due to increased bone formation. Sclerosteosis is associated with mutations in the SOST gene and Van Buchem disease with a 52 kb deletion downstream of the SOST gene that probably affects transcription of the gene. Expression of the gene product sclerostin in bone is restricted to osteocytes and it is a negative regulator of bone formation. It inhibits BMP-stimulated bone formation, but cannot antagonize all BMP responses. The exclusive bone phenotype of good quality of patients with sclerosteosis and Van Buchem disease and the specific localization of sclerostin make it an attractive target for the development of bone forming therapeutics. (c) 2005 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available